NM_000251.3(MSH2):c.387_388del (p.Gln130fs) AND Hereditary cancer-predisposing syndrome

Germline classification:
Pathogenic (1 submission)
Last evaluated:
Jun 14, 2022
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000491648.11

Allele description

NM_000251.3(MSH2):c.387_388del (p.Gln130fs)

Gene:
MSH2:mutS homolog 2 [Gene - OMIM - HGNC]
Variant type:
Microsatellite
Cytogenetic location:
2p21
Genomic location:
Preferred name:
NM_000251.3(MSH2):c.387_388del (p.Gln130fs)
HGVS:
  • NC_000002.11:g.47637253_47637254delTC
  • NC_000002.12:g.47410108TC[3]
  • NG_007110.2:g.11985TC[3]
  • NM_000251.3:c.387_388delMANE SELECT
  • NM_001258281.1:c.189_190del
  • NP_000242.1:p.Gln130fs
  • NP_001245210.1:p.Gln64fs
  • LRG_218:g.11985TC[3]
  • NC_000002.11:g.47637247TC[3]
  • NC_000002.11:g.47637247_47637248del
  • NC_000002.11:g.47637253_47637254delTC
  • NM_000251.1:c.387_388del
  • NM_000251.1:c.387_388delTC
  • NM_000251.2:c.387_388delTC
  • p.Gln130Valfs*2
Protein change:
Q130fs
Links:
dbSNP: rs63750924
NCBI 1000 Genomes Browser:
rs63750924
Molecular consequence:
  • NM_000251.3:c.387_388del - frameshift variant - [Sequence Ontology: SO:0001589]
  • NM_001258281.1:c.189_190del - frameshift variant - [Sequence Ontology: SO:0001589]
Observations:
1

Condition(s)

Name:
Hereditary cancer-predisposing syndrome
Synonyms:
Neoplastic Syndromes, Hereditary; Tumor predisposition; Cancer predisposition; See all synonyms [MedGen]
Identifiers:
MONDO: MONDO:0015356; MeSH: D009386; MedGen: C0027672

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000580392Ambry Genetics
criteria provided, single submitter

(Ambry General Variant Classification Scheme_2022)
Pathogenic
(Jun 14, 2022)
germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknown1not providednot provided1not providedclinical testing

Citations

PubMed

Somatic MMR gene mutations as a cause for MSI-H sebaceous neoplasms in Muir-Torre syndrome-like patients.

Joly MO, Attignon V, Saurin JC, Desseigne F, Leroux D, Martin-Denavit T, Giraud S, Bonnet-Dupeyron MN, Faivre L, Auclair J, Grand-Masson C, Audoynaud C, Wang Q.

Hum Mutat. 2015 Mar;36(3):292-5. doi: 10.1002/humu.22740.

PubMed [citation]
PMID:
25504677

Details of each submission

From Ambry Genetics, SCV000580392.5

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not provided1not providednot providedclinical testing PubMed (1)

Description

The c.387_388delTC pathogenic mutation, located in coding exon 3 of the MSH2 gene, results from a deletion of two nucleotides at nucleotide positions 387 to 388, causing a translational frameshift with a predicted alternate stop codon (p.Q130Vfs*2). One study identified three individuals heterozygous for this mutation in a Swiss HNPCC family: an individual diagnosed with colon cancer at age 57, an individual diagnosed with rectal cancer at age 46 who was also reported to have several adenomas of the colon, and an individual diagnosed with cancers of the nasopharynx and colon at ages 24 and 43, respectively. Furthermore, one untested obligate carrier in the family was reported to have a glioblastoma multiforme consistent with Turcot's syndrome (Buerstedde JM et al. J. Med. Genet. 1995 Nov;32(11):909-12). An additional study identified this mutation in a single individual with demonstrated absence of MSH2 protein on immunohistochemistry and low microsatellite instability on tumor testing (Lamberti C et al. Digestion 2006;74:58-67). This alteration was reported somatically in a sebaceous neoplasm with absent MSH2 and MSH6 protein (Joly MO et al. Hum. Mutat. 2015 Mar;36:292-5). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknown1not providednot provided1not providednot providednot provided

Last Updated: Apr 20, 2024